# NiKang Therapeutics Inc.: Research, Wilmington, United States

> NiKang Therapeutics Inc.: NiKang Therapeutics Inc. Based in Wilmington, United States. Founded 2017.

Source: https://millionrounds.com/startup/nikang-therapeutics-inc (Millionrounds; every figure on the page links to its filing or article)

United States · [Research startup](https://millionrounds.com/companies)

# NiKang Therapeutics Inc.

NiKang Therapeutics Inc.

Funding reported Last round: Series C

Research Wilmington, United States

Company summary

- **Founded:** 2017 9 years old
- **Team:** 36 11 to 50 people
- **Funding reported:** $260M in dollars
- **Last round:** Series C May 2021

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for NiKang Therapeutics Inc. has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About NiKang Therapeutics Inc.

NiKang Therapeutics Inc.

is a clinical-stage biotechnology company founded in 2017 and based in Wilmington, Delaware. The company is dedicated to developing innovative small molecule drugs aimed at treating cancer and addressing significant medical needs. With a team of approximately 41 employees, NiKang focuses on drug discovery within the Healthcare & Life Sciences sector, striving to create first-in-class and best-in-class precision medicines. The company specializes in oncology drug discovery, utilizing insights from disease biology and structure-based drug design. NiKang has advanced three small molecule drugs into first-in-human clinical testing, targeting challenging oncology areas such as HIF2α, CDK2, and KRAS G12D. Their drug pipeline includes NKT2152, a HIF2α inhibitor, NKT3447, which targets CDK2-dependent cancer cells, and compounds designed to inhibit the KRAS G12D mutation. NiKang aims to provide transformative therapies for patients with advanced cancers, particularly those with clear cell renal cell carcinoma.

## What company datasets say NiKang Therapeutics Inc. raised

Funding, as reported

Reported in all **$260M** in dollars

Rounds **3**

Last round **Series C**

Last round size **$200M**

Last round date **May 2021**

Investors listed **24**

## Founders and team

From NiKang Therapeutics Inc.'s own website and the SEC filings it signed: 5 on the team.

- **Zhenhai Gao** President, CEO, and Secretary i
- **Hong (Kelsey) Chen** Chief Financial Officer i
- **Chris Liu** Director
- **Denny Chu** Director
- **Wei Fu** Director

On the board, as filed i *Gary Yeung* *Roderick Wong* *Sean Cao* *Ting Jia* *Zhengbin Yao*

## The company, in detail

What they build

Known for

health care oncology targets biotechnology research structure-based drug design cancer therapy allosteric binding medical research difficult-to-drug targets small molecule drugs cdk2 degraders hospital & health care medical clinical-stage biotech health biotechnology target selectivity

Built with from their website

WordPress.org Font Awesome CloudFlare Viewport Meta WP Engine Underscore.js OWL Carousel Priority Hints Google Font API Microsoft Exchange

+8 more

MySQL PrimeNG wpBakery Microsoft 365 Apps & Services BambooHR Mobile Friendly Open Graph jQuery

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 2834, 8731
- **Region:** Delaware
- **Revenue:** $3.5M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/nikang-therapeutics)

## Research in United States

Startups like it

- [**OpenAI** San Francisco · founded 2011 *Raised*](https://millionrounds.com/company/openai)
- [**Retro Biosciences** Redwood City · founded 2021 *Raised*](https://millionrounds.com/company/retro-biosciences)
- [**NewLimit** South San Francisco · founded 2022 *Raised*](https://millionrounds.com/company/newlimit)
- [**Pathos** New York · founded 2022 *Raised*](https://millionrounds.com/company/pathos)
- [**Colossal Biosciences** Dallas · founded 2021 *Raised*](https://millionrounds.com/company/colossal-biosciences)
- [**Oratomic** South Pasadena *Raised*](https://millionrounds.com/company/oratomic)
- [**Beeline Medicines** Stamford · founded 2025 *Raised*](https://millionrounds.com/company/beeline-medicines)
- [**Element Biosciences** San Diego · founded 2017 *Raised*](https://millionrounds.com/company/element-biosciences)

## Is this your company?

Add your raise, your deck and your story, and put NiKang Therapeutics Inc. in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)